ADMINISTRATION OF A COMBINED ORAL CONTRACEPTIVE CONTAINING ESTRADIOL VALERATE/DIENOGEST (E2V/DNG) BY WOMEN WITH MENORRHAGIA

E. R. Dovlethanova, Е А Межевитинова, A. N. Mgeryan, П. Р. Абакарова
In: Medical Council · 2017 · pp. 31–37 · doi:10.21518/2079-701x-2017-2-31-37 · W3004340585
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-17 ⓘ

Estradiol valerate/dienogest (E2V/DNG) successfully reduced menstrual blood loss in reproductive-age women with menorrhagia not requiring surgical intervention.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-17 · read from full text ⓘ

This Russian paper describes use of a combined oral contraceptive containing estradiol valerate/dienogest (E2V/DNG) in women with menorrhagia, focusing on its administration and resulting effects as discussed in the publication. The study appears to draw on clinical evaluation within a menorrhagia population, but the provided text does not include sufficient details on sample size, study design, or measured outcomes to fully characterize methods or effect magnitude. A key limitation visible from the excerpt is that the full results and any explicitly stated caveats are not included here. Relevance to endometriosis: the paper’s scope is heavy menstrual bleeding/menorrhagia rather than endometriosis or adenomyosis, and the provided excerpt does not mention endometriosis or adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Menorrhagia is the pathological condition which is negatively affecting physical, emotional and social quality life of the woman. Medicines of the choice of therapy of uterine bleedings are the combined oral contraceptives (COC). The estradiol valerate/ dienogest (E2V/DNG), represents the combined oral contraceptive (COC) recommended for women as contraceptive. Gives to feature of influence of medicine on endometrium the chance of its application in case of uterine bleedings. The hormones which are a part suppress excessive proliferation of endometrium that leads to reduction of amount of menstrual allocations. Results of a research which confirm successful application of E2V/DNG in case of the menorrhagia at the women of reproductive age in clinical situations who aren’t requiring operational treatment are provided.
Full text 4,293 characters · extracted from oa-doi-fallback · click to expand
ПРИМЕНЕНИЕ КОМБИНИРОВАННОГО ОРАЛЬНОГО КОНТРАЦЕПТИВА, СОДЕРЖАЩЕГО ЭСТРАДИОЛА ВАЛЕРАТ/ДИЕНОГЕСТ (E2V/DNG), У ЖЕНЩИН С МЕНОРРАГИЕЙ https://doi.org/10.21518/2079-701X-2017-2-31-37 Аннотация Об авторах Э. Р. ДовлетхановаРоссия к.м.н., Москва Е. А. Межевитинова Россия д.м.н., Москва А. Н. Мгерян Россия к.м.н., Москва П. Р. Абакарова Россия к.м.н., Москва Список литературы 1. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. Под редакцией В.Н. Серова, Г.Т. Сухих, В.Н. Прилепской, В.Е. Радзинского. 3-е издание, переработанное и дополненное, ГЭОТАР-Медиа. 2016: 885-894. 2. Heavy Menstrual Bleeding. Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/women/menorrhagia.html/ 3. Fast Facts for Your Health: Menorrhagia. National Women’s Health Resource Center (NWHRC), Washington, D.C. http://www.healthywomen.org. 4. Menstruation: Heavy Bleeding (Menorrhagia). PreventDisease.com. http://preventdisease.com/diseases/menstruation_heavy_bleeding.html 5. Клинические рекомендации «Акушерство и гинекология». Под редакцией Г.М. Савельевой, В.Н. Серова, Г.Т. Сухих. 4-е издание, переработанное и дополненное, ГЭОТАР-Медиа, 2016, 1024 с. 6. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М. и др. Гормональная контрацепция. Москва, ГЭОТАР-Медиа, 2011, 256 с. 7. Women with Inherited Bleeding Disorders: Surgical Options for Menorrhagia. Canadian Hemophilia Society. http://www.hemophilia.ca/en/2.5.5.php. 8. Munro M.G., Critchley H.O., Broder M.S. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductiveage. FIGO Working Group on Menstrual Disorders. Int J Gynaecol Obstet, 2011, 113: 3–13. 9. National Collaborating Centre for Women’s and Children’s Health. National Institute for Health and Clinical Excellence (NICE). Heavy menstrual bleeding. London: Royal College of Obstetricians and Gynaecologists Press, 2007. 10. Heavy menstrual bleeding. Clinical guideline 44. London National Institute for Health and Clinical Excellence. January 2007. 11. Heavy menstrual bleeding. Quality standard. NICE /nice.org.uk/guidance/qs47. 2013. 12. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization, 2004. 13. Phillip CS, Faiz A, Dowling NF, Beckman M, Owens S, Ayers C, Bachmann G. Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. American Journal of Obstetrics & Gynecology, 2008, 198: 163.e1–163.e8. 14. Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. American Family Physician, 2007, 75: 1813-1820. http://www.aafp.org/afp/20070615/1813.html. 15. Heavy Bleeding and Endometrial Ablation. FertilityAnswers.com. http://www.fertilityanswers.com/endometrial_ablation.htm. 16. Menorrhagia (heavy menstrual bleeding). MayoClinic.com Health Library. http://www.riverside-online.com/health_reference/WomensHealth/DS00394.cfm. 17. De Leoa V, Fruzzettib F, Musacchioa MC, Scolaroa V, Di Sabatinoa A, Morgantea G. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception, 2013, 88: 364–368. 18. Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology, 1990, 97: 734–739. 19. Межевитинова Е.А., Бурлев В.А., Набиева К.Р., Ильясова Н.А., Иноземцева Е.А. Комплексная оценка эффективности, переносимости и безопасности комбинированного гормонального контрацептива третьего поколения. Медицинский совет, 2015, 9: 54-61. Рецензия Для цитирования: Довлетханова ЭР, Межевитинова ЕА, Мгерян АН, Абакарова ПР. ПРИМЕНЕНИЕ КОМБИНИРОВАННОГО ОРАЛЬНОГО КОНТРАЦЕПТИВА, СОДЕРЖАЩЕГО ЭСТРАДИОЛА ВАЛЕРАТ/ДИЕНОГЕСТ (E2V/DNG), У ЖЕНЩИН С МЕНОРРАГИЕЙ. Медицинский Совет. 2017;(2):31-37. https://doi.org/10.21518/2079-701X-2017-2-31-37 For citation: Dovlethanova ER, Mezhevitinova EA, Mgeryan AN, Abakarova PR. ADMINISTRATION OF A COMBINED ORAL CONTRACEPTIVE CONTAINING ESTRADIOL VALERATE/DIENOGEST (E2V/DNG) BY WOMEN WITH MENORRHAGIA. Meditsinskiy sovet = Medical Council. 2017;(2):31-37. (In Russ.) https://doi.org/10.21518/2079-701X-2017-2-31-37 JATS XML

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (6)

Source provenance

openalex
last seen: 2026-05-10T10:52:06.415033+00:00
License: CC0 · commercial use OK